Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06535789
PHASE2/PHASE3

Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes

Sponsor: Jaeb Center for Health Research

View on ClinicalTrials.gov

Summary

Pregnant women aged 18-40 with gestational diabetes (GDM) will take part in this study. We want to see how two different insulin treatments affect their blood sugar after they eat. These women usually use a rapid-acting insulin analog (RAA) that's injected to control their blood sugar before and after meals. They will come to the clinic for two meal sessions. For the first meal, we will randomly decide if they will use the usual RAA insulin or a newer inhaled insulin called technosphere insulin (TI). They will use the other type of insulin for their second meal. After each meal, we will compare their blood sugar levels.

Official title: The Safety and Efficacy of Rapid Acting Inhaled Technosphere Insulin (Afrezza) Compared With Subcutaneous Insulin to Achieve Pregnancy-Specific Postprandial Targets Among Patients With Gestational Diabetes

Key Details

Gender

FEMALE

Age Range

18 Years - 40 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2025-05

Completion Date

2025-07

Last Updated

2025-05-15

Healthy Volunteers

No

Interventions

DRUG

Inhaled Technosphere Insulin

Patients will receive TI (Afrezza) to be compared to RAA following a breakfast meal

Locations (5)

Sansum Diabetes Research Institute

Santa Barbara, California, United States

University of Colorado Anschutz Medical Campus

Aurora, Colorado, United States

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Oregon Health and Science University

Portland, Oregon, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States